Michael York - 20 May 2021 Form 4 Insider Report for PhaseBio Pharmaceuticals Inc

Reporting relationship: VP, Corporate Development
Issuer ticker: N/A
Reported as of: 20 May 2021
Net transaction value: +$8,112
SEC form: 4
Accepted by SEC: 24 May 2021, 18:10:24 UTC
Next SEC filing: 24 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ John P. Sharp, Attorney-in-fact

Key filing fact

Michael York filed Form 4 for PhaseBio Pharmaceuticals Inc on 24 May 2021.

Key facts

This page summarizes Michael York's Form 4 filing for PhaseBio Pharmaceuticals Inc.
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 24 May 2021, 18:10.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: +$8,112.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PHASQ transaction

Common Stock

Award

Transaction value: $8,112
Shares: +2,897
Change %: +70%
Price: $2.80^*
Shares after: 7,059
Date: 20 May 2021
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

These shares were acquired under the PhaseBio Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).